FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA

Congress spotlights J&J stent ops

Tools

Who's the drug watchdog's watchdog? Congress, of course--and it's barking at the FDA and Johnson & Johnson. Late yesterday, the House Committee on Energy and Commerce asked for more information about contamination problems the drug agency found in 2004 at J&J's Cordis unit, which makes a drug-coated stent called Cypher. The FDA sent a letter to Cordis at the time, notifying the company of "systemic violations" that caused the stents to be adulterated during the manufacturing process.

Now, the committee wants to know why J&J was allowed to continue selling the Cypher stents--and it plans to dig through emails, notes, reports, and the like, plus interview people at the FDA and J&J.

- read the report from The Wall Street Journal (sub. req.)

Related Articles:
Medical device makers to fund stent safety study. Report
Stent study surprises. Report
Decline in drug-coated stent use at cardiac centers. Report
Insurers may cut stent payouts. Report

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about FDA  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.